Medindia

X

Misonix Schedules Second Quarter 2010 Financial Results Conference Call; February 16, 2010 at 4:30 P.M. Eastern

Friday, February 12, 2010 Press Release J E 4
Advertisement


FARMINGDALE, N.Y., Feb. 11 Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced plans to release second quarter ended December 31, 2009 financial results on Tuesday afternoon, February 16, 2010. Michael A. McManus, President and Chief Executive Officer and Richard Zaremba, Senior VP and Chief Financial Officer, will host a conference call at 4:30 p.m. Eastern on Tuesday, February 16, 2010 to discuss the Company's second quarter 2010 financial results.

Shareholders and other interested parties may participate in the conference call by dialing (866) 730 5768 (domestic) or (857) 350 1592 (international) and entering access code 79394029, a few minutes before the start of the call. A simultaneous webcast will be available via Misonix's website at www.misonix.com. The call will be archived on the Company's website for at least 90 days.

A recording of the live-call will be available approximately 2 hours after the event through February 23, 2010. The dial-in number to listen to the recording is (888) 286 8010 or (617) 801 6888. The replay access code is 15380068.

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Investor Relations Contact: Kevin M. McGrath Cameron Associates, Inc. 212 245 4577 Kevin@cameronassoc.com

SOURCE Misonix, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Amicus Therapeutics Presents Positive Data Update ...
S
Patients with Lethal Lung Disease Finally Receive ...